Biocon Biologics Secures Insulin Supply Agreement Renewal from Malaysia's MOH

Image Source : EquityBulls

Extended Partnership Bolsters Biocon's Position in Southeast Asia

Biocon Biologics has been granted a six-month agreement extension by the Malaysian Ministry of Health (MOH) for insulin supply to public hospitals. This renewal commits Biocon further to making high-quality and affordable insulin available to Malaysia's healthcare environment.

Contract Extension: Biocon Biologics' contract to supply insulin for six months has been extended by the Malaysian MOH, guaranteeing steady supply of vital diabetes medication.

Public Healthcare Support: The contract allows Biocon to continue playing an important role in being a major insulin supplier for public hospitals in Malaysia.

Market Impact: The extension is indicative of high demand for Biocon's insulin products, affirming its stronghold in the Southeast Asian market for pharmaceuticals.

Strategic Expansion: Biocon Biologics continues to further its presence in global insulin supply, enhancing its alliances with medical facilities.

Biocon Biologics has long been a biosimilar insulin leader, making the product accessible to patients in Malaysia and further afield. This extension of the contract underscores the confidence and trust Biocon has garnered in the country.

Source:The Edge Malaysia, The Star, Luminews.